EP0196920B1 - Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation - Google Patents

Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation Download PDF

Info

Publication number
EP0196920B1
EP0196920B1 EP86302424A EP86302424A EP0196920B1 EP 0196920 B1 EP0196920 B1 EP 0196920B1 EP 86302424 A EP86302424 A EP 86302424A EP 86302424 A EP86302424 A EP 86302424A EP 0196920 B1 EP0196920 B1 EP 0196920B1
Authority
EP
European Patent Office
Prior art keywords
species
enzyme
protein
degraded
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86302424A
Other languages
German (de)
English (en)
Other versions
EP0196920A3 (en
EP0196920A2 (fr
Inventor
Ian C/O Smithkline Beecham Pharmaceuticals Dodd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0196920A2 publication Critical patent/EP0196920A2/fr
Publication of EP0196920A3 publication Critical patent/EP0196920A3/en
Application granted granted Critical
Publication of EP0196920B1 publication Critical patent/EP0196920B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a degraded species of an enzyme, the isolation of that species, pharmaceutical compositions containing that species and its use in the treatment of thrombotic disease.
  • tissue-type plasminogen activator t-PA
  • t-PA tissue-type plasminogen activator
  • M molecular weight
  • the species will hereinafter be designated alanine 6o-proline 527 t-PA (ala 160 -pro 527 -t-PA).
  • the degraded species is at least 70% pure when measured by a conventional method such as sodium dodecylsulphate polyacrylamide gel electrophoresis.
  • the degraded species is at least 80% pure and more preferably at least 95% pure.
  • the degraded species has a molecular weight in the region of 38,000-40,000.
  • the invention further provides a method for the preparation of a degraded species of t-PA as herein defined, which method comprises expressing DNA encoding said degraded species in a recombinant host cell and recovering the degraded t-PA product.
  • the method of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular cloning - A Laboratory Manual; Cold Spring Harbor, 1982.
  • the native t-PA employed in the separation process is partially purified (for example as described in M.J. Browne et al, 1985, Gene 33,279).
  • the chromatography may be carried out using an appropriate molecular weight sieve for example Sephadex.
  • At least two chromatography steps are employed. Concentration for example by means of ultrafiltration is preferably effected after each chromatography step.
  • the degraded species has a molecular weight of around 38,000.
  • t-PA of the invention may be derivatised to provide pharmaceutically useful conjugates analogous to known t-PA-containing conjugates, for example:
  • the degraded species of t-PA of the invention may take the place of t-PA as the enzyme or (human) protein component, as appropriate, of any of the conjugates described above.
  • the degraded species of t-PA or conjugate thereof can be further derivatised such that any catalytic site essential for fibrinolytic activity is optionally blocked by a removable blocking group.
  • a fibrinolytically active degraded species of tissue-type plasminogen activator as defined, wherein the catalytic site essential for fibrinolytic activity is blocked by a removable blocking group.
  • Suitable optional substituents for benzoyl blocking groups included halogen, C, - 6 alkyl, C 1-6 alkoxy, C, - 6 alkanoyloxy, C, - 6 alkanoylamino, amino or p-guanidino.
  • Suitable optional substituents for acryloyl blocking groups include C 1-6 alkyl, furyl, phenyl or C 1-6 alkylphenyl.
  • Examples of a removable blocking groups include p-anisoyl and N,N-dimethyl 4-amino benzoyl.
  • Blocking of the active centre with a removable blocking group can be effected by methods described in European Patent No. 0009879.
  • the t-PA species of the invention is suitably administered in the form of a pharmaceutical composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a fibrinolytically active degraded species of t-PA or derivative thereof as herein defined in combination with a pharmaceutically acceptable carrier.
  • compositions for intravenous administration are solutions of the sterile enzyme in sterile isotonic aqueous buffer.
  • the composition may also include a solubilising agent to keep the degraded t-PA species in solution and a local anaesthetic such as lignocaine to ease pain at the site of injection.
  • a local anaesthetic such as lignocaine to ease pain at the site of injection.
  • the t-PA species of the invention will be supplied in unit dosage form for example as a dry powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of protein in activity units.
  • the t-PA species includes a removable blocking group an indication of the time within which the free protein will be liberated may be given.
  • the protein is to be administered by infusion, it will be dispensed with an infusion bottle containing sterile pharmaceutical grade 'Water for Injection' or saline. Where the protein is to be administered by injection, it is dispensed with an ampoule of sterile water or saline.
  • the injectable or infusable composition will be made up by mixing the ingredients prior to administration.
  • the quantity of material administered will depend upon the amount of fibrinolysis required and the speed with which it is required, the seriousness of the thromboembolic condition and position and size of the clot.
  • the precise dose to be employed and mode of administration must per force in view of the nature of the complaint be decided according to the circumstances by the physician supervising treatment.
  • a patient being treated for a mature thrombus will generally receive a daily dose of from 0.01 to 10 mg/kg of body weight either by injection in for example up to five doses or by infusion.
  • a method of treating thrombotic diseases which comprises administering to the sufferer an effective non-toxic amount of a fibrinolytically active degraded species of t-PA or derivative thereof as herein defined.
  • the invention further provides a fibrinolytically active degraded species of t-PA or derivative thereof as herein defined, for use as an active therapeutic substance and, in particular, for use in the treatment of thrombotic diseases.
  • Tissue-type plasminogen activator secreted into serum-free media by recombinant Bowes melanoma cells was shown by SDS PAGE (Laem- mli, U.K., 1970, Nature, 227, 680-682) followed by fibrin zymography (Granelli-Piperno, A. and Reich, E., 1978, J. Exp. Med., 148, 223-234) to contain several species of t-PA. All the t-PA species were purified by chromatography on zinc chelate and lysine Sepharose * (Browne, M.J. et al, 1985, Gene, 33, 279) and concentrated by ultra-filtration.
  • the fibrin-binding test employed was similar to that of Rijken, D.C. and Collen, D. (J. Biol. Chem. (1981) 256, 7035).
  • Essentially plasminogen activator-containing fibrinogen solution was treated with or without thrombin and any precipitable material (eg. fibrin) isolated by centrifugation.
  • the supernatants were assayed using a fibrin plate assay (as described in Example 7).
  • the difference in activator concentration between the supernatants of the two treatments (with or without thrombin) was equivalent to the amount of material adsorbed to the clot.
  • heparin 50 U/kg i.v.
  • compound under test Approximately 5 min after heparinization, a pre-dose blood sample was taken and mixed with 0.1 volumes 129 mM trisodium citrate. The compound under test was then injected (1 ml/kg) over 10s. Further blood samples were taken exactly 2, 4, 8, 16, 30 and 60 min later. Heparin treatment (50 U/kg i.v.) was repeated after the 30 min sample to maintain cannula patency. All citrated blood samples were kept on ice until the end of each experiment, then centrifuged at 1700g for 15 min at 4°C to obtain plasma.
  • the euglobulin fraction was precipitated by adding 0.1 ml of each plasma to 1.82 ml ice-cold 0.011% (v/v) acetic acid in water. After 30 min standing in ice, all tubes were centrifuged at 1700 g for 15 min at 4°C. The supernatants were poured away, the inner walls of each tube carefully wiped dry and each precipitate redissolved in 0.4 ml phosphate-buffered saline, pH 7.4, containing 0.01% (v/v) Tween 80. Aliquots (30 ⁇ l) were then applied to fibrin plates in quadruplicate.
  • Fibrin plates were prepared from 0.4% (w/v) human fibrinogen (Kabi, Grade L, Flow Laboratories, Scotland) dissolved in 0.029 M barbitone in 125 mM NaCI, pH 7.4, pipetted (10 ml) into 10 x 10 cm square plastic dishes (Sterilin) and clotted by rapid mixing with 0.3 ml bovine thrombin (50 NIH units/ml, Parke-Davis, U.K.). Plates were incubated at 37 °C for 18-24h usually, but longer if required, and stained with aqueous bromophenol blue. For each lysis zone, two diameters perpendicular to each other were measured using Vernier callipers.
  • DAB N'N'-dimethyl 4-aminobenzoyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (10)

1. Espèce dégradée purifiée ayant une activité fibrinolytique d'activateur de plasminogène tissulaire comprenant une chaîne B intacte du point de vue fibrinolytique de t-PA naturel liée au kringle 2 en tant qu'unique domaine intact du point de vue fonctionnel et structurel de la chaîne A de t-PA naturel.
2. Espèce suivant la revendication 1, ayant un poids moléculaire dans la région de 38.000 à 40.000.
3. Espèce suivant la revendication 2, ayant un poids moléculaire voisin de 38.000.
4. Espèce dégradée purifiée de t-PA ayant l'alanine 160 comme résidu d'acide aminé N-terminal.
5. Dérivé d'une espèce suivant l'une quelconque des revendications précédentes choisi parmi :
(a) un conjugué enzyme-protéine dans lequel le site catalytique sur l'enzyme qui est responsable de l'activité fibrinolytique est bloqué par une protéine humaine fixée à celui-ci au moyen d'un groupe de liaison réversible.
(b) une conjugué enzyme-protéine comprenant au moins une enzyme fibrinolytique éventuellement bloquée lié au moyen d'un site autre que le site catalytique responsable de l'activité fibrinolytique à au moins une protéine humaine;
(c) un conjugué protéine-polymère comprenant une protéine utile du point de vue pharmaceutique liée à au moins un polymère soluble dans l'eau au moyen d'un groupe de liaison réversible; ou
(d) un conjugué d'enzymes comprenant un certain nombre d'enzymes fibrinolytiques liées ensemble par leurs centres actifs au moyen d'un groupe bloquant pouvant être éliminé;

dans lequel l'espèce dégradée de t-PA est l'enzyme ou le composant protéine (humain), selon ce qui convient, d'un quelconque des conjugués (a) à (d).
6. Dérivé suivant la revendication 5, dans lequel un quelconque site catalytique essentiel pour l'activité fibrinolytique est éventuellement bloqué par un groupe bloquant pouvant être éliminé.
7. Espèce dégradée de N,N'-diméthyl-4-aminobenzoyl-t-PA ayant un alanine 160 comme résidu d'acide aminé N-terminal ou espèce dégradée de p-anisoyl-t-PA ayant un alanine 160 comme résidu d'acide aminé N-terminal.
8. Composition pharmaceutique comprenant une espèce suivant l'une quelconque des revendications 1 à 7, en association avec un support acceptable du point de vue pharmaceutique.
9. Espèce suivant l'une quelconque des revendications 1 à 7, utilisable dans le traitement de maladies thrombotiques.
10. Procédé pour la préparation d'une espèce suivant les revendications 2, 3 ou 4, qui comprend la séparation de l'espèce du t-PA naturel obtenue à partir d'une lignée cellulaire sécrétant du t-PA.
EP86302424A 1985-04-03 1986-04-02 Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation Expired - Lifetime EP0196920B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858508717A GB8508717D0 (en) 1985-04-03 1985-04-03 Composition
GB8508717 1985-04-03

Publications (3)

Publication Number Publication Date
EP0196920A2 EP0196920A2 (fr) 1986-10-08
EP0196920A3 EP0196920A3 (en) 1988-07-27
EP0196920B1 true EP0196920B1 (fr) 1994-07-06

Family

ID=10577147

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86302424A Expired - Lifetime EP0196920B1 (fr) 1985-04-03 1986-04-02 Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation

Country Status (5)

Country Link
US (1) US4970159A (fr)
EP (1) EP0196920B1 (fr)
JP (1) JP2631645B2 (fr)
DE (1) DE3689943T2 (fr)
GB (1) GB8508717D0 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8609948D0 (en) * 1986-04-23 1986-05-29 Beecham Group Plc Compounds
US5234686A (en) * 1985-04-03 1993-08-10 Beecham Group P.L.C. Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
US5106741A (en) * 1985-12-20 1992-04-21 The Upjohn Company Tissue plasminogen activator (TPA) analogs
CA1341444C (fr) * 1986-01-24 2003-10-21 Margaret Y. Insley Activateur tissulaire du plasminogene modifie
JPH01500322A (ja) * 1986-03-28 1989-02-09 クリエイティブ　バイオモレクレス，インコーポレーテッド 組織プラスミノーゲンアクテイベーター類縁蛋白質
US5242819A (en) * 1986-12-05 1993-09-07 Ciba-Geigy Corporation DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase
US5580559A (en) * 1986-12-05 1996-12-03 Ciba-Geigy Corporation Hybrid plasminogen activator
IE880255L (en) * 1987-01-30 1988-07-30 American Home Prod Des-epidermal growth factor activators.
JPH084502B2 (ja) * 1987-03-20 1996-01-24 エーザイ株式会社 複合変異ｔＰＡ
US6682733B1 (en) * 1987-06-18 2004-01-27 Roche Diagnostics, Gmbh Fibrinolytic enzymes
DE3886755T3 (de) * 1987-06-30 2005-12-08 Genentech, Inc., South San Francisco Verfahren zur behandlung von gefässkrankheiten.
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US5244676A (en) * 1987-10-09 1993-09-14 Monsanto Company Modified tissue plasminogen activator with modified glycosylation site
US5100666A (en) * 1987-10-09 1992-03-31 Monsanto Company Modified tissue plasminogen activator K2K2SP
US4999194A (en) * 1988-01-14 1991-03-12 Collaborative Research, Inc. Two-chain urokinase plasminogen activators for treatment of thrombotic disease
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
US5037646A (en) * 1988-04-29 1991-08-06 Genentech, Inc. Processes for the treatment of vascular disease
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
ATE132373T1 (de) * 1991-04-16 1996-01-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DK0827751T3 (da) * 1996-09-06 2003-03-31 Chemo Sero Therapeut Res Inst Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
GR79202B (fr) * 1982-05-05 1984-10-22 Genentech Inc
EP0234051B1 (fr) * 1986-02-17 1991-12-11 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Mutants de l'activateur de plasminogène tissulaire; information recombinante génétique codant pour celui-ci et procédéde préparation de ces mutants, leur application et compositions pharmaceutiques

Also Published As

Publication number Publication date
GB8508717D0 (en) 1985-05-09
DE3689943T2 (de) 1994-10-20
EP0196920A3 (en) 1988-07-27
JPS61243024A (ja) 1986-10-29
US4970159A (en) 1990-11-13
DE3689943D1 (de) 1994-08-11
JP2631645B2 (ja) 1997-07-16
EP0196920A2 (fr) 1986-10-08

Similar Documents

Publication Publication Date Title
EP0196920B1 (fr) Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation
EP0155387B1 (fr) Protéine hybride à activité fibrinolytique, son procédé de préparation et composition pharmaceutique
JPH0378375B2 (fr)
Collen et al. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
JP2003514790A (ja) 可逆的に不活性化された酸性化プラスミンの局所送達による血栓溶解の方法
EP0151593B1 (fr) Derives enzymatiques
EP0383417B1 (fr) Activateur du plasminogène salivaires de chauve-souris vPA-alpha 1
RU2143490C1 (ru) Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство
US6008019A (en) Plasminogen activator from saliva of the vampire bat
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
US4999194A (en) Two-chain urokinase plasminogen activators for treatment of thrombotic disease
JPH0647555B2 (ja) フィブリン親和性ウロキナーゼ複合体含有血栓溶解剤
EP0381640B1 (fr) Compositions trombolitiques
EP0487660B1 (fr) Traitement de la thrombose
EP0421918B1 (fr) Compositions pharmaceutiques
US5908625A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
EP0181596B1 (fr) Procédé de préparation d'un complexe d'urokinase
WO1992018139A1 (fr) Molecules chimeriques ayant une activite d'activation de plasminogene et affinite pour les plaques atherosclerotiques
JP2000504941A (ja) トロンビンによって活性化され得るプラスミノーゲンアクチベーター
Robison et al. Activators of Plasminogen
WO1996017928A1 (fr) Utilisation du domaine protease de l'activateur plasminogene humain dans le traitement de maladies thromboemboliques
WO1991019793A2 (fr) Activateurs de plasminogene hybrides
MXPA99000966A (en) Plasminogen activator capable of being activated by thrombin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE FR GB IT LI NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE CH DE FR GB IT LI NL

17P Request for examination filed

Effective date: 19890316

17Q First examination report despatched

Effective date: 19900829

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEECHAM GROUP PLC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DODD, IAN, C/O SMITHKLINE BEECHAM PHARMACEUTICALS

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE FR GB IT LI NL

REF Corresponds to:

Ref document number: 3689943

Country of ref document: DE

Date of ref document: 19940811

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050314

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050316

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050401

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20050413

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050428

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050429

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050613

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060402

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20060402

BE20 Be: patent expired

Owner name: *BEECHAM GROUP P.L.C.

Effective date: 20060402